Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr;11(2):97-102.
doi: 10.1007/s12328-018-0841-9. Epub 2018 Feb 28.

The genetic backgrounds in nonalcoholic fatty liver disease

Affiliations
Review

The genetic backgrounds in nonalcoholic fatty liver disease

Yuya Seko et al. Clin J Gastroenterol. 2018 Apr.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH), a severe form of NAFLD, can lead to hepatocellular carcinoma (HCC) and hepatic failure. The development and progression of NAFLD are determined by environmental and genetic factors. The effect of genetic factors has been demonstrated by familial studies, twin studies and several cross-sectional studies. In the past 10 years, genome-wide association studies have revealed several single nucleotide polymorphisms (SNPs) associated with the pathology of NAFLD. Among them, the Patatin-like phospholipase domain-containing 3 (PNPLA3) gene variant I148M showed a strong relationship with the development and progression of NAFLD, NASH, and NAFLD-related HCC. The transmembrane 6 superfamily member 2 (TM6SF2) gene variant E167 K was also associated with NAFLD, and it has a relationship with cardiovascular disease. Furthermore, several genes have been proposed as candidate genes to be associated with NAFLD based on case-control studies. We conducted a comprehensive literature search and review on the genetic background of NAFLD.

Keywords: Genome-wide association study (GWAS); Glucokinase regulator (GCKR); Nonalcoholic fatty liver disease (NAFLD); PNPLA3; TM6SF2.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Am J Gastroenterol. 2001 Oct;96(10):2957-61 - PubMed
    1. Hepatol Res. 2015 Apr;45(4):363-77 - PubMed
    1. BMC Gastroenterol. 2012 Aug 16;12:111 - PubMed
    1. Diabetes. 2010 Dec;59(12):3127-30 - PubMed
    1. J Gastroenterol Hepatol. 2015 Jan;30(1):21-7 - PubMed

MeSH terms

Substances

LinkOut - more resources